Pharmacological evaluation of IQM-95,333, a highly selective CCK(A) receptor antagonist with anxiolytic-like activity in animal models

British Journal of Pharmacology

Volumn 121, Issue 4, 1997, Pages 759-767

  Ballaz, Santiago ^a   Barber, Ana ^a   Fortuño, Ana ^a   Del Río, Joaquín ^a,c   Martín Martínez, Mercedes ^b   Gómez Monterrey, Isabel ^b   Herranz, Rosario ^b   González Muñiz, Rosario ^b   García López, Maria Teresa ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Amylase release; Anxiolytic drugs; CCK(A) receptors; CCK(B) receptors; Cholecystokinin (CCK); Food intake

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; AMYLASE; ANXIOLYTIC AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; DEVAZEPIDE; IQM 95333; LORGLUMIDE; PD 135158; TETRAGASTRIN; UNCLASSIFIED DRUG;

ACINAR CELL; AMYLASE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; EXPLORATORY BEHAVIOR; FOOD INTAKE; GUINEA PIG; HYPOPHAGIA; ILEUM; INTESTINE MUSCLE; LOCOMOTION; MALE; MOUSE; MUSCLE CONTRACTION; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RECEPTOR BINDING;

AMYLASES; ANIMALS; ANOREXIA; ANTI-ANXIETY AGENTS; BENZODIAZEPINONES; CARBAMATES; CHOLECYSTOKININ; DEVAZEPIDE; DIAZEPAM; DISEASE MODELS, ANIMAL; FENFLURAMINE; GUINEA PIGS; HORMONE ANTAGONISTS; LOCOMOTION; MALE; MICE; PHENYLUREA COMPOUNDS; PYRIMIDINONES; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; SEROTONIN UPTAKE INHIBITORS;

EID: 0030954561     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701186     Document Type: Article

References (66)

1. A receptor antagonist. Br. J. Pharmacol., 117, 1558-1564.
2. +-channel agonists or antagonists other than sulphonylureas. Fundum. Clin. Pharmacol., 5, 107-115.
3. 3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology, 117, 137-148.
4. BRADWEJN, J., KOSZYCKI, D., PARADIS, M., REECE, P., HINTON, J. & SEDMAN, A. (1995). Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol. Psychiat., 38, 742-746.
5. BRADWEJN, J., KOSZYCKI, D. & SHRIQUI, C. (1991). Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioural findings. Arch. Gen. Psychiat., 48, 603-610.
6. CATTERALL, W.A., MORROW, C.S. & HARTSHORNE, R.P. (1979). Neurotoxin binding to receptor sites associated with voltage-sensitive sodium channels in intact, lysed, and detergent-solubilized brain membranes. J. Biol. Chem. 254, 11379-11387.
7. CHANG, R.S.L. & LOTTI, V.J. (1986). Biochemical and pharmacological characterization of an extremely potent and selective nonpeplide cholecystokinin antagonist. Proc. Natl. Acad. Sci. U.S.A., 83, 4923-4926.
8. CHARRIER, D., DANGOUMAU, L., PUECH A.J., HAMON, M. & THIEBOT, M.H. (1995). Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology, 121, 127-134.
9. 50) of an ezymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
10. COOPER, S.J., DOURISH, C.T. & BARBER, D.J. (1990). Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329. Br. J. Pharmacol., 99, 65-70.
11. COSTALL, B., DOMENEY, A.M., HUGHES, J., KELLY, M.E., NAYLOR, R.J. & WOODRUFF, G.N. (1991). Anxiolytic effects of CCK-B antagonists. Neuropeptides, 19, (Suppl.) 65-73.
12. CRAWLEY, J.N. & GOODWIN, F.K. (1980). Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav., 13, 167-170.
13. CRAWLEY, J.N., HAYS, S.E. & PAUL, S.M. (1981). Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behavior. Eur. J. Pharmacol., 73, 379-380.
14. DAL FORNO, G., PIETRA, C., URCIOULI, M., VAN AMSTERDAM, F.T.M., TOSON, G., GAVIGARHI, G. & TRIST, D. (1992). Evidence for two cholecystokinin receptor mediating the contraction of guinea pig isolated ileum longitudinal muscle myenteric plexus. J. Pharmacol. Exp. Ther., 261, 1056-1063.
15. B receptors by using a new highly potent CCK analog: BC 264. Synapse, 6, 73-80.
16. A receptors of the postero-median part of the nucleus accumbens. Pharmacol. Biochem. Behav., 34, 157-163.
17. DE FELIPE, M.C., MOLINERO, M.T. & DEL RIO, J. (1989). Long-lasting neurochemical and functional changes in rats induced by neonatal administration of substance P antiserum. Brain Res., 485, 301-308.
18. DE MONTIGNY, C. (1989). Cholecystokinin-tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiat., 46, 511-517.
19. A receptors. Eur. J. Pharmacol., 173, 233-234.
20. EBERLE-WANG, K. & SIMANSKY, K.J. (1992). The CCK-A receptor antagonist, devazepide, blocks the anorectic action of CCK but not peripheral serotonin in rats. Pharmacol. Biochem. Behav., 43, 943-947.
21. FURCHGOTT, R.F. (1972). The classification of adrenoreceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In Handbook of Experimental Pharmacology, ed. Blaschko, H. & Muscholl, E., pp. 283-335. Berlin: Springer.
22. GONZÁLEZ-MUÑIZ, R., GÓMEZ-MONTERREY, Y., MARTÍN-MARTÍNEZ, M., HERRANZ, R., GARCÍA-LÓPEZ, M.T., BARBER, A., BALLAZ, S. & DEL RÍO, J. (1996). 1,3-Dioxoperhydropyrido [1,2-c] pyrimidines. Novel, potent and selective cholecystokinin-A receptor antagonists. Abstr. 24th Symposium European Peptide Society, Edinburgh P132.
23. HENDRIE, C.A. & DOURISH, C.T. (1990). Anxiolytic profile of the cholecystokinin antagonist devazepide in mice. Br. J. Pharmacol., 99, 138P.
24. B antagonists on activity in the black/white exploration model of anxiety in mice. Physiol. Behav., 54, 689-693.
25. HEWSON, G., LEIGHTON, G.E., HILL, R.G. & HUGHES, J. (1988). The cholecystokinin receptor antagonist L-364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br. J. Pharmacol., 93, 79-84.
26. HILL, D.R., HUGHES, J. & PITTAWAY, K.M. (1987). Antinociceptive action of cholecystokinin octapeptide (CCK) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors. Neuropharmacology, 26, 289-300.
27. HILL, D.R., SINGH, L., BODEN, P., PINNOCK, R., WOODRUFF, G.N. & HUGHES, J. (1992). Detection of CCK receptor subtypes in mammalian brain using highly selective non-peptide antagonists. In Multiple Cholecystokinin Receptors in the CNS, ed. Dourish, C.T., Cooper, S.J., Iversen, S.D. & Iversen, L.L., pp. 57-76. Oxford: Oxford University Press.
28. HILL, D.R. & WOODRUFF, G.N. (1990). Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res., 526, 276-283.
29. HUGHES, J., BODEN, P., COSTALL, B., DOMENEY, A., KELLY, E., HORWELL, D.C., HUNTER, J.C., PINNOCK, R.D. & WOODRUFF, G.N. (1990). Development of a class of selective cholecystokinin type B receptor antagonists having anxiolytic activity. Proc. Natl. Acad. Sci. U.S.A., 87, 6728-6732.
30. 3 recognition sites in membranes of NIE-115 neroblastoma cells by radioligand binding. Mol. Pharmacol., 33, 303-309.
31. INNIS, R.B. & SNYDER, S.H. (1980). Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. U.S.A., 77, 6917-6921.
32. ITO, H., SOGABE, H., NAKARAI, T., SATO, Y., TOMOI, M., KADOWAKI, M., MATSUO, M., TOKORO, K. & YOSHIDA, K. (1994). Pharmcological profile of FK 480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. J. Pharmacol. Exp. Ther., 268, 571-575.
33. JENSEN, R.T., LEMP, G.F. & GARDNER, J.D. (1982). Interactions of COOH-terminal fragments of cholecystokinin with receptors on dispersed acini from guinea pig pancreas. J. Biol. Chem., 257, 5554-5559.
34. JENSEN, R.T., WANG, S.A., ROWLEY, W.H., SATO, S. & GARDNER, J.D. (1989). Interaction of CCK with pancreatic acinar cells. Trends Pharmacol. Sci., 10, 418-423.
35. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology, 124, 355-362.
36. KHOSLA, S. & CRAWLEY, J.N. (1988). Potency of L-364,718 as an antagonist of the behavioural effects of peripherally administered cholecystokinin. Life Sci., 42, 153-159.
37. B antagonist, in panic disorder. Biol. Psychiat., 37, 462-466.
38. KUWAHARA, T., KUDOH, T., NAKANO, A., YOSHIZAKI, H., TAKAMIYA, M., NAGASE, H. & ARISAWA, M. (1993). Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci. Lett., 158, 1-4.
39. 3H] (+)PN 200-110 binding to dihydropyridine receptors associated with calcium channels in rat cerebral cortex and heart. Life Sci., 35, 721-732.
40. B) ligand: L-365,260. Eur. J. Physiol., 162, 273-280.
41. LUCAITES, V.L., MENDELSOHN, L.G., MASON, N.R. & COHEN, M.L. (1991). CCK-8, CCK-4 and gastrin-induced contractions in guinea pig ileum: evidence for differential release of acetylcholine and substance P by CCK-A and CCK-B receptors. J. Pharmacol. Exp. Ther., 256, 695-703.
42. LUGRIN, D., VECCHINI, F., DOULLUT, S., RODRIGUEZ, M., MARTINEZ, J. & KITABGI, P. (1991). Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Eur. J. Pharmacol., 205, 191-198.
43. MAKOVEC, F., CHRISTER, R., BANI, R., PACINI, M.A., STENIKAR, I. & ROVATI, A.L. (1985). New glutaramic acid derivatives with potent competitive and specific cholecystokinin antagonist activity. Arzneim-Forsch. Drug Res., 35, 1048-1051.
44. MORAN, T.H., ROBINSON, P.H., GOLDRICH, M.S. & MCHUGH, P.R. (1986). Two brain cholecystokinin receptors: implications for the behavioral actions. Brain Res., 362, 175-179.
45. B receptor antagonist L-365,260. Eur. J. Pharmacol, 193, 203-208.
46. PATEL, M. & SPRAGGS, C.F. (1992). Studies of gastrin/CCK receptors using functional isolated preparations. In Multiple Cholecystokinin Receptors in the CNS, ed. Dourish, C.T., Cooper, S.J., Iversen, S.D. & Iversen, L.L., pp. 98-106. Oxford: Oxford University Press.
47. PATON, V.D. & VIZI, E.S. (1969). The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea pig ileum longitudinal muscle strip. Br. J. Pharmacol., 35, 10-28.
48. PEIKIN, S.R., ROTTMAN, A.J., BATZRI, S. & GARDNER, J.D. (1978). Kinetics of amylase release by dispersed acini prepared from guinea pig pancreas. Am. J. Physiol. 235, E743-E749.
49. PENDLEY, C.E., FITZPATRICK, L.R., CAPOLINO, A.J., DAVIS, M.A., ESTERLINE, N.J., JAKUBOWSKA, A., BERTRAND, P, GUYON, C., DUBROEUQE, M.C. & MARTIN, G.E. (1995). RP73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J. Pharmacol. Exp. Ther., 273, 1015-1022.
50. PONCELET, M., ARNONE, M., HEAULME, M., GONALONS, N., GUEUDET, C., SANTUCCI, V., THURNEYSSEN, O., KEANE, P., GULLY, D., LE FUR, G. & SOUBRIE, P. (1993). Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 102-107.
51. PROUS, R.J. ed. (1995). The Year's Drug News. Therapeutic Targets. Barcelona/Philadelphia: Prous Science.
52. RASSMUSSEM, K., CZACURA, J.F., STOCKTON, M.E. & HOWBERT, J.J. (1993). Electrophysiological effects of diphenyl pyrozolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther., 264, 480.
53. REIDELBERGER, R.D., VARGA, G., LIEHR, R.F., CASTELLANOS, D.A., ROSENQUIST, G.L., WONG, H.C. & WALSH, J.H. (1994). Cholecystokinin suppresses food intake by a nonendocrine mechanism in rats. Am. J. Physiol., 267, R901-R908.
54. REX, A., BARTH, T., VOIGT, J-P., DOMENEY, A.M. & FINK, H. (1994). Effects of cholecystokinin tetrapeptide and sulphated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett., 172, 139-142.
55. 3 receptor antagonists in development as anxiolytics. Exp. Opin. Invest. Drugs, 4, 333-342.
56. SILVENTE-POIROT, S., DUFRESNE, M., VAYSSE, N. & FOURMY, D. (1993). The peripheral cholecystokinin receptors. Eur. J. Biochem., 215, 513-429.
57. B receptor antagonist. Br. J. Pharmacol., 104, 239-245.
58. SINGH, L., LEWIS, A.S., FIELD, M.J., HUGHES, J. & WOODRUFF, G.N. (1991b). Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. U.S.A., 88, 1130-1133.
59. SOAR, J., HEWSON, G., LEIGHTON, G.E., HILL, R.G. & HUGHES, J. (1989). L-365,260 antagonizes the cholecystokinin-induced suppression of locomotor activity. Pharmacol. Biochem. Behav., 33, 637-640.
60. 3H] flunitrazepam binding. Life Sci., 24, 351-358.
61. A receptor antagonist, in vitro. Eur. J. Pharmacol., 304, 147-154.
62. VOGEL, J.R., BEER, B. & CLODY, D.E. (1971). A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology, 21, 1-7.
63. WATKINS, L.R., KINSHECK, I.B. & MAYER, D.J. (1983). Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science, 224, 395-396.
64. WETTSTEIN, J.G., BUENO, L. & JUNIEN, J.L. (1994). CCK antagonists: pharmacological and therapeutic interest. Pharmacol. Ther., 62, 267-284.
65. WILLIAMS, J.A. & BLEVINS, G.T. (1993). Cholecystokinin and regulation of pancreatic acinal cell function. Physiol. Rev., 73, 701-723.
66. WOODRUFF, G.N., HILL, D.R., BODEN, P., PINNOCK, R., SINGH, L. & HUGHES, J. (1991). Functional role of brain CCK receptors. Neuropeptides, 19 (Suppl.), 45-56.